MD, New York University School of Medicine
PhD, New York University School of Medicine
Internship, Brigham and Womens Hospital, Harvard Medical School,
In Situ, Autologous Therapeutic Vaccination Against Solid Cancers with Intratumoral Hiltonol
This study will test the safety of a course of injections containing Poly-ICLC, an investigational drug, in patients with solid tumors that can be easily and safely reached with a needle. An investigational drug is one that has not been approved by the U.S. Food and Drug Ad...
PHASE I, OPEN LABEL, STUDY OF PGV001 A MULTI-PEPTIDE THERAPEUTIC VACCINE PLATFORM FOR THE TREATMENT OF SOLID TUMORS IN THE ADJUVANT SETTING
The purpose of this study is to use an experimental vaccine known as Personalized Genome Vaccine 001 or PGV001 to learn more about the body's ability to fight cancer. By definition, an experimental vaccine is not approved by the United States Food and Drug Administration (F...
A Phase II, Open-label, Multicenter, Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients with Malignant Melanoma Pre-Treated with Recombinant CDX-301, a Recombinant Human Flt3 Ligand
The purpose of this study is to see if the biologic drug CDX-301 (Flt3L) makes the immune response to a combination of a cancer vaccine (CDX-1401) and another biologic drug (poly-ICLC) better. A biologic is a drug that is made from living organisms or their products to use ...
Phase II open label, randomized study of Poly-ICLC matured DC as an adjuvant for NY-ESO-1 and Melan-A/Mart-1 peptide vaccination compared to Montanide® ISA-51 VG, in patients with melanoma in complete clinical remission but a high risk of disease recurrence
The purpose of this study is to use an experimental vaccine to learn more about the body's ability to fight cancer. The study consists of two different treatment groups (also known as study arms), identified as study ARM A and ARM B. Both study arms use an experimenta...
da Silva IP, Gallois A, Jimenez-Baranda S, Khan S, Anderson AC, Kuchroo VK, Osman I, Bhardwaj N. Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade. Cancer immunology research 2014 May; 2(5).
Harshman LC, Drake CG, Wargo JA, Sharma P, Bhardwaj N. Cancer immunotherapy highlights from the 2014 ASCO Meeting. Cancer immunology research 2014 Aug; 2(8).
Miller E, Bhardwaj N. Advances in dendritic cell immunotherapies for HIV-1 infection. Expert opinion on biological therapy 2014 Nov; 14(11).
Bloch N, O'Brien M, Norton TD, Polsky SB, Bhardwaj N, Landau NR. HIV type 1 infection of plasmacytoid and myeloid dendritic cells is restricted by high levels of SAMHD1 and cannot be counteracted by Vpx. AIDS research and human retroviruses 2014 Feb; 30(2).
Fernandez MV, Miller EA, Bhardwaj N. Activation and measurement of NLRP3 inflammasome activity using IL-1β in human monocyte-derived dendritic cells. Journal of visualized experiments : JoVE 2014;(87).
Sivendran S, Chang R, Pham L, Phelps RG, Harcharik ST, Hall LD, Bernardo SG, Moskalenko MM, Sivendran M, Fu Y, de Moll EH, Pan M, Moon JY, Arora S, Cohain A, DiFeo A, Ferringer TC, Tismenetsky M, Tsui CL, Friedlander PA, Parides MK, Banchereau J, Chaussabel D, Lebwohl MG, Wolchok JD, Bhardwaj N, Burakoff SJ, Oh WK, Palucka K, Merad M, Schadt EE, Saenger YM. Dissection of immune gene networks in primary melanoma tumors critical for antitumor surveillance of patients with stage II-III resectable disease. The Journal of investigative dermatology 2014 Aug; 134(8).
Manches O, Frleta D, Bhardwaj N. Dendritic cells in progression and pathology of HIV infection. Trends in immunology 2014 Mar; 35(3).
Godefroy E, Gallois A, Idoyaga J, Merad M, Tung N, Monu N, Saenger Y, Fu Y, Ravindran R, Pulendran B, Jotereau F, Trombetta S, Bhardwaj N. Activation of toll-like receptor-2 by endogenous matrix metalloproteinase-2 modulates dendritic-cell-mediated inflammatory responses. Cell reports 2014 Dec; 9(5).
Bhardwaj N, Brody JD. Dendritic cells and lymphoma cells: come together right now. Blood 2015 Jan; 125(1).
Moogk D, da Silva IP, Ma MW, Friedman EB, de Miera EV, Darvishian F, Scanlon P, Perez-Garcia A, Pavlick AC, Bhardwaj N, Christos PJ, Osman I, Krogsgaard M. Melanoma expression of matrix metalloproteinase-23 is associated with blunted tumor immunity and poor responses to immunotherapy. Journal of translational medicine 2014; 12(1).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Bhardwaj during 2015 and/or 2016. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Scientific Advisory Board:
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.